Gain new key opinion leader (KOL) insights on the latest events happening in prostate cancer.
Topics covered include expert opinions on; the results of the Phase III LATITUDE and STAMPEDE trials investigating J&J’s Zytiga (abiraterone) plus prednisone, in combination with androgen deprivation therapy (ADT) in patients with hormone-naïve prostate cancer (HNPC); KOL views on the results published in the Cancer Discovery journal which suggest that a blood test measuring circulating free DNA (cfDNA) can be used to assess treatment response in men with advanced prostate cancer who are administered with AstraZeneca's PARP inhibitor Lynparza (olaparib). Finally, the experts provide candid insights into their expectations for Array BioPharma’s and Roche’s Akt inhibitor ipatasertib, which entered Phase III development for patients with metastatic castration-resistant prostate cancer (mCRPC) in May 2017.
Business Questions:
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved